HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.

Abstract
We assessed the efficacy of prolonged interferon-alpha (IFN) therapy in children with chronic hepatitis caused by hepatitis delta virus (HDV) by treating 26 paediatric cases with IFN-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 (medium-term group MTG) or 24 months (long-term group, LTG). Compliance and tolerability were acceptable. At the end of therapy a complete biochemical response [normalization of alanine aminotransferase (ALT)] occurred in 12 children (5/13 in MTG and 7/13 in LTG). A relapse occurred after stopping IFN in 10 cases (five in MTG and five in LTG). Two patients from the LTG had normal liver function tests during 12 months of follow-up. Six of the eight hepatitis B e antigen (HBeAg) positive children lost HBeAg, while all six hepatitis B virus (HBV) DNA positive patients lost HBV DNA during treatment. HBeAg reappeared later in two children. HDV RNA, present in 10/10 cases of MTG before treatment, persisted after 12 months IFN therapy in 3/10. One year after stopping therapy, 8/10 patients were again HDV RNA positive. Two children cleared hepatitis delta antigen (HDVAg) from the liver. No significant improvements in liver histology were seen in both groups. Our experience suggests that IFN-alpha treatment in children with chronic type D hepatitis has a transient effect, and long-term treatment does not appear to induce a greater therapeutic benefit in terms of biochemical and virological response.
AuthorsV Di Marco, R Giacchino, A Timitilli, F Bortolotti, C Crivellaro, R Calzia, C Iannuzzi, T Prestileo, P Vajro, G Nebbia, C Stringhi, F Rosina, D Biassoni, F Callea, M Rizzetto, A Craxi
JournalJournal of viral hepatitis (J Viral Hepat) Vol. 3 Issue 3 Pg. 123-8 (May 1996) ISSN: 1352-0504 [Print] England
PMID8871870 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Viral
  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B e Antigens
  • Interferon Type I
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Alanine Transaminase
Topics
  • Adolescent
  • Alanine Transaminase (analysis)
  • Antigens, Viral (analysis)
  • Antiviral Agents (administration & dosage, adverse effects, therapeutic use)
  • Child
  • Chronic Disease
  • DNA, Viral (analysis)
  • Female
  • Hepatitis B e Antigens (analysis)
  • Hepatitis B virus (genetics)
  • Hepatitis D (blood, drug therapy)
  • Hepatitis Delta Virus (genetics, immunology)
  • Humans
  • Interferon Type I (administration & dosage, adverse effects, therapeutic use)
  • Interferon-alpha (administration & dosage, adverse effects, therapeutic use)
  • Male
  • Patient Compliance
  • RNA, Viral (analysis)
  • Recombinant Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: